The Subject Expert Committee (SEC) is likely to meet today to take up Sputnik V application for Emergency Use Authorisation (EUA) in India, said sources.
Russia's Sputnik V vaccine did not get the EUA on Thursday as the SEC, following the meeting, asked for more information.
According to the sources, 'The SEC has asked for more information in context with the approval of the Russian vaccine."
The committee, set up by the government, looked into Dr Reddy's application seeking approval for the vaccine to be used in India. The Russian vaccine has an effectiveness of 91.6 per cent. Dr Reddy's Lab has partnered with the Russia Direct Investment Fund (RDIF) to bring the Sputnik V vaccine to India and other countries.
Russia registered Sputnik V for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September.
Top government sources told ANI that by end of the third quarter of this year, India will be getting vaccines from five additional manufacturers. India currently manufactures Covishield and Covaxin.
When a top-level source was asked when the vaccines will be available for use, he said, "Sputnik is expected to be available latest by June, if all goes well Johnson and Johnson ( Bio E) will be available by August, Cadilla Zydus will also be available by August, Novavex (Serum) by September and Nasal Vaccine (Bharat) by October."
The Government is making all efforts to accelerate the progress without cutting any corners in research, development, and clinical trial stages, the source added.
India is currently facing the second wave of COVID-19 pandemic with the number of new cases increasing each day.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU